Unicycive Therapeutics (UNCY) Amortizatization of Intangibles (2020 - 2026)
Unicycive Therapeutics posted quarterly Amortizatization of Intangibles of $203000.0 for Q1 2026, up 59.84% year-on-year from $127000.0 in Q1 2025, and up 97.09% on a QoQ basis from $103000.0 in Q4 2025.
Unicycive Therapeutics (UNCY) has 7 years of Amortizatization of Intangibles data on file, last reported at $203000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles rose 59.84% year-over-year to $203000.0; the trailing twelve-month figure through Mar 2026 stood at $576000.0 (up 123.26% YoY), and the FY2025 full-year result was $500000.0, up 23.15% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $203000.0, up from $103000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $275000.0 in Q1 2024 and bottomed at -$113000.0 in Q2 2024.
- The 5-year median for Amortizatization of Intangibles is $79000.0 (2023), against an average of $90470.6.
- Peak annual rise in Amortizatization of Intangibles reached 539.53% in 2024, while the deepest fall reached 248.68% in 2024.
- A 5-year view of Amortizatization of Intangibles shows it stood at $40000.0 in 2022, then soared by 97.5% to $79000.0 in 2023, then soared by 60.76% to $127000.0 in 2024, then declined by 18.9% to $103000.0 in 2025, then soared by 97.09% to $203000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $203000.0 (Q1 2026), $103000.0 (Q4 2025), and $138000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | 203,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 203,000.00 |
| Mar 31, 2026 | 203,000.00 |
| Dec 31, 2025 | 103,000.00 |
| Dec 31, 2025 | 103,000.00 |
| Sep 30, 2025 | 138,000.00 |
| Sep 30, 2025 | 138,000.00 |
| Jun 30, 2025 | 132,000.00 |
| Jun 30, 2025 | 132,000.00 |
| Mar 31, 2025 | 127,000.00 |
| Mar 31, 2025 | 127,000.00 |
| Dec 31, 2024 | 127,000.00 |
| Dec 31, 2024 | 127,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Jun 30, 2024 | -113,000.00 |
| Jun 30, 2024 | -113,000.00 |
| Mar 31, 2024 | 275,000.00 |
| Mar 31, 2024 | 275,000.00 |
| Dec 31, 2023 | 79,000.00 |
| Dec 31, 2023 | 79,000.00 |
| Sep 30, 2023 | 77,000.00 |
| Sep 30, 2023 | 77,000.00 |
| Jun 30, 2023 | 76,000.00 |
| Jun 30, 2023 | 76,000.00 |
| Mar 31, 2023 | 43,000.00 |
| Mar 31, 2023 | 43,000.00 |
| Dec 31, 2022 | 40,000.00 |
| Dec 31, 2022 | 40,000.00 |
| Sep 30, 2022 | 39,000.00 |
| Sep 30, 2022 | 39,000.00 |
| Jun 30, 2022 | 38,000.00 |
| Jun 30, 2022 | 38,000.00 |
| Mar 31, 2022 | 37,000.00 |
| Mar 31, 2022 | 37,000.00 |
| Dec 31, 2021 | -476,000.00 |
| Dec 31, 2021 | -476,000.00 |
| Sep 30, 2021 | 41,000.00 |
| Sep 30, 2021 | 41,000.00 |
| Jun 30, 2021 | 250,000.00 |
| Jun 30, 2021 | 250,000.00 |
| Mar 31, 2021 | 197,000.00 |
| Mar 31, 2021 | 197,000.00 |
| Dec 31, 2020 | 127,000.00 |
| Dec 31, 2020 | 127,000.00 |